Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OJSY: LOL look at the spread on that! .03 X 2,000
ECCI: Looking good for a move up today.
PLYCF: at HOD, should break it here imo
PLYCF:LOL mm games. Bringing it down on nothing
PLYCF: Buy or Die!! lol
PLYCF: Gap of the century! LOL Chart looks great
lol, too lazy. Go BCIT!
Better than a bush
AXGJ: gapping here. Looking great
I have a sell order in on BCIT for 10k shares and it's been there for the last 20 minutes. Using TradingDirect
PLYCF: gapping nicely this morning. Going to run again today imo.
PLYCF: New HOD!
I agree. I see PLYCF hitting .02 tomorrow.
Keep an eye on UDTT here. Had big news.
SLJB: gapping .175/18 4X2
Yeah, SLJB on its way back to the .20's imo
SLJB: 17's are up! Something big must be coming!
Agree. SLJB should see .20's again next week?
AMRE: adding to my position for next weeks news.
AMRE: I agree. Chart set up great.
CTXI going to explode this afternoon
XKEM huge loan news out!!!
AMRE: Will continue to run into tomorrow.
MCET NEWS: MultiCell Technologies Files Milestone Patent to Treat Cancer
Thursday, September 28 2006 4:01 PM, EST
MultiCell Technologies, Inc. (OTCBB: MCET), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced the filing of a milestone patent that provides a potential method for treating a range of malignant tumors using the Company's unique technologies to manipulate the immune system.
MSRGW low floater up huge today. Possible gapper?
UPDA: Gapping this morning. News yesterday
ACTC: form out saying there will be a shareholder meeting on Oct 13 to vote on raising the AS from 100mil to 500 mil
Email sent stockholder.. Where you at?
GLIF: rant Life Sciences Inc. (OTC BB: GLIF) announced today that ithas received a purchase order from an arm of the Indian government fortwo million of its point-of-care (POC), 'rapid' malaria tests
GLIF: news
AAGH: Looks good
NWBT: FDA Clearance to proceed with cancer vaccine trials..
-Northwest Biotherapeutics, Inc. today announced that it has received FDA clearance to proceed with Phase I clinical testing of its personalized therapeutic cancer vaccine, DCVax-LB, in non-small cell lung cancer. The clinical endpoints of the trial will be progression-free survival and overall survival.
ACTC: Gap and run tomorrow imo. nice eod push
ACTC: big news! Government funding??
AMZB - Huge AIDS FDA Approval News!!!!
Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection
NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the UnitedStates Patent and Trademark Office, advising that Amazon's application forpatent protection of its investigative drug named AMZ0026 has beenapproved.
AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drugcandidate and is currently approved by the FDA to undergo Phase I/IIstudies in humans. AMZ0026 has been shown to exhibit potentialtherapeutically beneficial effects on the immune system of immunodeficientHIV/AIDS patients, particularly with respect to elevation of CD4 levels inpreliminary clinical case studies.
Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are verypleased to receive the notice of allowance. We believe that this eventsignificantly strengthens our intellectual property rights and increasesour potential value."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarilydeveloping immune modulator drugs. AMZ0026 is the company's first suchdrug, which is to be used for the treatment of HIV/AIDS. The company planson initiating Phase I/II clinical studies of AMZ0026 in the near future,with an eventual goal of attracting a joint venture partner with a majorpharmaceutical company in Phase III trials, or follow the FDA Fast Trackprogram to market. Amazon Biotech specializes in natural plantpharmaceutical drugs and is focused on bringing healthier pharmaceuticaldrugs to market.
Additional information on Amazon Biotech may be found at:Amazon Biotech.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Actof 1995 This press release contains forward-looking information within themeaning of Section 21E of the Securities Exchange Act of 1934, includingstatements regarding any potential sales of products as well as statementsthat include the words "believes," "expects," "anticipates," or similarexpressions. Such forward-looking statements involve known and unknownrisks, uncertainties and other factors that may cause the actual results,performance or achievements of Amazon Biotech, to differ materially fromthose implied or expressed by such forward-looking statements. Such factorsinclude, among others, the risk factors included in Amazon Biotech'ssubsequent reports filed with the Securities and Exchange Commission underthe Exchange Act. This press release speaks as of the date first set forthabove and Amazon Biotech assumes no responsibility to update theinformation included herein for events occurring after the date hereof.
Contact:LC GroupRick Lutz(404) 261-1196
Just wanted to point out.. Could be big runner tomorrow..
AMZB - Huge AIDS FDA Approval News!!!!
Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection
NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the UnitedStates Patent and Trademark Office, advising that Amazon's application forpatent protection of its investigative drug named AMZ0026 has beenapproved.
AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drugcandidate and is currently approved by the FDA to undergo Phase I/IIstudies in humans. AMZ0026 has been shown to exhibit potentialtherapeutically beneficial effects on the immune system of immunodeficientHIV/AIDS patients, particularly with respect to elevation of CD4 levels inpreliminary clinical case studies.
Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are verypleased to receive the notice of allowance. We believe that this eventsignificantly strengthens our intellectual property rights and increasesour potential value."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarilydeveloping immune modulator drugs. AMZ0026 is the company's first suchdrug, which is to be used for the treatment of HIV/AIDS. The company planson initiating Phase I/II clinical studies of AMZ0026 in the near future,with an eventual goal of attracting a joint venture partner with a majorpharmaceutical company in Phase III trials, or follow the FDA Fast Trackprogram to market. Amazon Biotech specializes in natural plantpharmaceutical drugs and is focused on bringing healthier pharmaceuticaldrugs to market.
Additional information on Amazon Biotech may be found at:Amazon Biotech.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Actof 1995 This press release contains forward-looking information within themeaning of Section 21E of the Securities Exchange Act of 1934, includingstatements regarding any potential sales of products as well as statementsthat include the words "believes," "expects," "anticipates," or similarexpressions. Such forward-looking statements involve known and unknownrisks, uncertainties and other factors that may cause the actual results,performance or achievements of Amazon Biotech, to differ materially fromthose implied or expressed by such forward-looking statements. Such factorsinclude, among others, the risk factors included in Amazon Biotech'ssubsequent reports filed with the Securities and Exchange Commission underthe Exchange Act. This press release speaks as of the date first set forthabove and Amazon Biotech assumes no responsibility to update theinformation included herein for events occurring after the date hereof.
Contact:LC GroupRick Lutz(404) 261-1196
AMZB - Huge AIDS FDA Approval News!!!!
Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection
NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the UnitedStates Patent and Trademark Office, advising that Amazon's application forpatent protection of its investigative drug named AMZ0026 has beenapproved.
AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drugcandidate and is currently approved by the FDA to undergo Phase I/IIstudies in humans. AMZ0026 has been shown to exhibit potentialtherapeutically beneficial effects on the immune system of immunodeficientHIV/AIDS patients, particularly with respect to elevation of CD4 levels inpreliminary clinical case studies.
Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are verypleased to receive the notice of allowance. We believe that this eventsignificantly strengthens our intellectual property rights and increasesour potential value."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarilydeveloping immune modulator drugs. AMZ0026 is the company's first suchdrug, which is to be used for the treatment of HIV/AIDS. The company planson initiating Phase I/II clinical studies of AMZ0026 in the near future,with an eventual goal of attracting a joint venture partner with a majorpharmaceutical company in Phase III trials, or follow the FDA Fast Trackprogram to market. Amazon Biotech specializes in natural plantpharmaceutical drugs and is focused on bringing healthier pharmaceuticaldrugs to market.
Additional information on Amazon Biotech may be found at:Amazon Biotech.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Actof 1995 This press release contains forward-looking information within themeaning of Section 21E of the Securities Exchange Act of 1934, includingstatements regarding any potential sales of products as well as statementsthat include the words "believes," "expects," "anticipates," or similarexpressions. Such forward-looking statements involve known and unknownrisks, uncertainties and other factors that may cause the actual results,performance or achievements of Amazon Biotech, to differ materially fromthose implied or expressed by such forward-looking statements. Such factorsinclude, among others, the risk factors included in Amazon Biotech'ssubsequent reports filed with the Securities and Exchange Commission underthe Exchange Act. This press release speaks as of the date first set forthabove and Amazon Biotech assumes no responsibility to update theinformation included herein for events occurring after the date hereof.
Contact:LC GroupRick Lutz(404) 261-1196
havent been around the boards recently... What's causing the increase in XKEM? Expecting news?
ACTC: picking up steam
ACTC: mostly buys. Moving up finally i think..